91 related articles for article (PubMed ID: 38542198)
21. Cancer and Apoptosis.
Chaudhry GE; Akim AM; Sung YY; Muhammad TST
Methods Mol Biol; 2022; 2543():191-210. PubMed ID: 36087269
[TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase-2 Upregulated by Temozolomide in Glioblastoma Cells Is Shuttled In Extracellular Vesicles Modifying Recipient Cell Phenotype.
Lombardi F; Augello FR; Artone S; Ayroldi E; Giusti I; Dolo V; Cifone MG; Cinque B; Palumbo P
Front Oncol; 2022; 12():933746. PubMed ID: 35936755
[TBL] [Abstract][Full Text] [Related]
23. Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors.
Ahmadi M; Bekeschus S; Weltmann KD; von Woedtke T; Wende K
RSC Med Chem; 2022 May; 13(5):471-496. PubMed ID: 35685617
[TBL] [Abstract][Full Text] [Related]
24. Pioglitazone Hydrochloride Extends the Lifespan of
Jia W; Wang C; Zheng J; Li Y; Yang C; Wan QL; Shen J
Oxid Med Cell Longev; 2022; 2022():8496063. PubMed ID: 35677109
[TBL] [Abstract][Full Text] [Related]
25. Potential Therapeutic Effects of PPAR Ligands in Glioblastoma.
Basilotta R; Lanza M; Casili G; Chisari G; Munao S; Colarossi L; Cucinotta L; Campolo M; Esposito E; Paterniti I
Cells; 2022 Feb; 11(4):. PubMed ID: 35203272
[TBL] [Abstract][Full Text] [Related]
26. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
27. Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism.
Yin D; Jin G; He H; Zhou W; Fan Z; Gong C; Zhao J; Xiong H
Aging (Albany NY); 2021 Sep; 13(17):21268-21282. PubMed ID: 34497154
[TBL] [Abstract][Full Text] [Related]
28. Discovery of pyrazole N-aryl sulfonate: A novel and highly potent cyclooxygenase-2 (COX-2) selective inhibitors.
Yao H; Guo Q; Wang M; Wang R; Xu Z
Bioorg Med Chem; 2021 Sep; 46():116344. PubMed ID: 34438337
[TBL] [Abstract][Full Text] [Related]
29. Celecoxib repurposing in cancer therapy: molecular mechanisms and nanomedicine-based delivery technologies.
Khafaga AF; Shamma RN; Abdeen A; Barakat AM; Noreldin AE; Elzoghby AO; Sallam MA
Nanomedicine (Lond); 2021 Aug; 16(19):1691-1712. PubMed ID: 34264123
[TBL] [Abstract][Full Text] [Related]
30. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Louis DN; Perry A; Wesseling P; Brat DJ; Cree IA; Figarella-Branger D; Hawkins C; Ng HK; Pfister SM; Reifenberger G; Soffietti R; von Deimling A; Ellison DW
Neuro Oncol; 2021 Aug; 23(8):1231-1251. PubMed ID: 34185076
[TBL] [Abstract][Full Text] [Related]
31. Drug Repurposing: Claiming the Full Benefit from Drug Development.
Kort E; Jovinge S
Curr Cardiol Rep; 2021 May; 23(6):62. PubMed ID: 33961142
[TBL] [Abstract][Full Text] [Related]
32. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
[TBL] [Abstract][Full Text] [Related]
33. CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing
Ye X; Liu X; Gao M; Gong L; Tian F; Shen Y; Hu H; Sun G; Zou Y; Gong Y
Front Oncol; 2021; 11():638802. PubMed ID: 33869025
[TBL] [Abstract][Full Text] [Related]
34. PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action.
Hernandez-Quiles M; Broekema MF; Kalkhoven E
Front Endocrinol (Lausanne); 2021; 12():624112. PubMed ID: 33716977
[TBL] [Abstract][Full Text] [Related]
35. Plasticity of cancer cell invasion: Patterns and mechanisms.
Wu JS; Jiang J; Chen BJ; Wang K; Tang YL; Liang XH
Transl Oncol; 2021 Jan; 14(1):100899. PubMed ID: 33080522
[TBL] [Abstract][Full Text] [Related]
36. Single-cell dynamics of pannexin-1-facilitated programmed ATP loss during apoptosis.
Imamura H; Sakamoto S; Yoshida T; Matsui Y; Penuela S; Laird DW; Mizukami S; Kikuchi K; Kakizuka A
Elife; 2020 Oct; 9():. PubMed ID: 33052098
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma.
Shono K; Yamaguchi I; Mizobuchi Y; Kagusa H; Sumi A; Fujihara T; Nakajima K; Kitazato KT; Matsuzaki K; Saya H; Takagi Y
Sci Rep; 2020 Sep; 10(1):15286. PubMed ID: 32943658
[TBL] [Abstract][Full Text] [Related]
38. The Extracellular Matrix and Biocompatible Materials in Glioblastoma Treatment.
Belousov A; Titov S; Shved N; Garbuz M; Malykin G; Gulaia V; Kagansky A; Kumeiko V
Front Bioeng Biotechnol; 2019; 7():341. PubMed ID: 31803736
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro.
Uram Ł; Misiorek M; Pichla M; Filipowicz-Rachwał A; Markowicz J; Wołowiec S; Wałajtys-Rode E
Molecules; 2019 Oct; 24(20):. PubMed ID: 31652556
[TBL] [Abstract][Full Text] [Related]
40.
Wittkowski P; Marx-Stoelting P; Violet N; Fetz V; Schwarz F; Oelgeschläger M; Schönfelder G; Vogl S
Environ Sci Technol; 2019 Nov; 53(21):12725-12733. PubMed ID: 31536708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
